论文部分内容阅读
目的 研究孕妇血清乙型肝炎表面抗原 (HBsAg)、乙型肝炎e抗原 (HBeAg)滴度与其新生儿接种乙型肝炎 (乙肝 )疫苗发生免疫失败的关系 ,探讨能否用孕妇血清HBsAg、HBeAg滴度代替血清HBVDNA浓度来衡量新生儿接种乙肝疫苗后发生免疫失败的危险性。方法 178例HB sAg、HBeAg双阳性母亲的新生儿接种乙肝疫苗后 ,随访至 2 4月龄 ,32例发生免疫失败 ,用斑点杂交法检测孕妇临产前血清乙型肝炎病毒 (HBV)DNA浓度、用酶联免疫吸附试验 (ELISA)法测定孕妇HBsAg和HBeAg滴度 ,研究孕妇HBsAg、HBeAg的滴度与其新生儿接种疫苗发生免疫失败的关系 ,并与孕妇血清HBVDNA浓度与其新生儿发生免疫失败的关系相比较。结果 随着母亲血清HB sAg、HBeAg滴度的升高 ,其新生儿发生免疫失败的危险性升高 ,当孕妇血清HBsAg滴度≥ 1∶10 0 0、HBeAg滴度≥ 1∶10 0时 ,分别有 2 6 .3%、31.4%的新生儿发生乙肝疫苗免疫失败 ,与当孕妇血清HBVDNA浓度≥ 12 5pg/ml,新生儿发生免疫失败的危险性相当。 结论 孕妇血清HBsAg、HBeAg高滴度与其新生儿接种疫苗发生免疫失败有密切联系 ,孕妇血清HBsAg滴度≥ 1∶10 0 0、HBeAg滴度≥ 1∶10 0能够代替血清HBVDNA浓度≥ 12 5 pg/ml作为衡量孕妇的乙肝高传染性的指标来预测新生儿发生免疫失败的危险?
Objective To study the relationship between serum hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) titer in pregnant women and the immune failure of their newborns with Hepatitis B vaccine (hepatitis B), and to explore whether the serum HBsAg, HBeAg Degree instead of serum HBVDNA to measure the risk of immunological failure of neonates after hepatitis B vaccination. Methods A total of 178 newborns with HBsAg and HBeAg positive mothers were followed up to 24 months of age and 32 cases were immunocompromised. HBV DNA levels in pregnant women before pregnancy were detected by dot blot hybridization. The serum HBsAg and HBeAg titers were measured by enzyme-linked immunosorbent assay (ELISA). The relationship between the titer of HBsAg and HBeAg in pregnant women and the immune failure of newborns vaccinated were studied. The relationship between serum HBVDNA levels and neonatal immunocompromised Compare the relationship. Results With the increase of maternal serum HBsAg and HBeAg titer, the risk of immune failure in neonates was increased. When the serum HBsAg titer of the pregnant women was ≥ 1:10 0 and the HBeAg titer was ≥ 1:10, Respectively, 26.3%, 31.4% of newborns with hepatitis B vaccine failed to immunize, which is equivalent to the risk of immune failure in newborns when serum HBVDNA concentration is more than 125pg / ml in pregnant women. Conclusions High serum HBsAg and HBeAg titer in pregnant women is closely related to the immune failure of newborns vaccinated. The serum HBsAg titer of pregnant women is ≥ 1:10 0, and the HBeAg titer ≥ 1:10 can replace the serum HBVDNA ≥ 125 pg / ml as a measure of high HBV infection in pregnant women to predict the risk of neonatal immune failure?